BCDA

BioCardia Inc

0.9210

Oct 23 • 3:59 PM ET -0.0077 (-0.83%)

0.9394

Aftermarket • 7:30 PM ET +0.0184 (2.00%)

Healthcare Biotechnology USA Nano NASD

Peers: CAPR LGVN MESO TNYA CELZ PLUR BRTX LSTA CVKD KARD

| Held by: VXF VTI

Scroll to Statements

Index	-
Market Cap	13.94M
Enterprise Value	10.11M
Income	-7.34M
Sales	0.00M
Book/sh	0.18
Cash/sh	0.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Nov 13, 1996

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.11
P/C	3.38
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.09
Current Ratio	2.09
Debt/Eq	0.11
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.76
EPS next Y	-0.52
EPS next Q	-0.13
EPS this Y	48.78%
EPS next Y	18.25%
EPS next 5Y	31.52%
EPS past 3/5Y	50.34% 43.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	63.72%
Sales Y/Y TTM	-100.00%
EPS Q/Q	67.06%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	27.78% -

Insider Own	23.74%
Insider Trans	4.91%
Inst Own	9.06%
Inst Trans	9.66%
ROA	-214.47%
ROE	-1803.19%
ROIC	-271.81%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.11%
SMA50	-12.72%
SMA200	-15.37%
Trades

Shs Outstand	14.98M
Shs Float	11.54M
Short Float	5.37%
Short Ratio	2.44
Short Interest	0.62M
52W High	1.80 -48.83%
52W Low	0.75 22.80%
Volatility	10.85% 6.78%
ATR (14)	0.08
RSI (14)	41.21
Beta	0.67
Rel Volume	0.16
Avg Volume	253.82K
Volume	40,319

Perf Week	0.10%
Perf Month	-13.93%
Perf Quarter	13.94%
Perf Half Y	-20.60%
Perf YTD	-26.32%
Perf Year	-33.98%
Perf 3Y	-83.79%
Perf 5Y	-97.82%
Perf 10Y	-99.48%
Recom	1.00
Target Price	15.50
Prev Close	0.93
Price	0.92
Change %	-0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Oct-19-26 09:15AM	BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter (GlobeNewswire)
Oct-07-26 09:00AM	BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-01-26 09:15AM	BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix Catheter (GlobeNewswire)
Sep-23-26 09:15AM	BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission (GlobeNewswire)
Sep-10-26 08:30AM	BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
08:30AM	Loading…
Aug-24-26 08:30AM	BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval (GlobeNewswire)
Aug-13-26 01:04AM	BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... (GuruFocus.com) +5.56%
Aug-12-26 04:05PM	BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results (GlobeNewswire) -5.59%
Aug-05-26 03:16PM	BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 (GlobeNewswire)
Jun-18-26 08:00AM	BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities (GlobeNewswire)
Jun-08-26 08:00AM	BioCardia Announces $4.4 Million Financing (GlobeNewswire) -10.68%
Jun-05-26 12:25PM	Why Did BCDA Stock Surge More Than 50% Today? (Stocktwits) +12.08%
10:31AM	BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) (InvestorsHub)
08:00AM	FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF (GlobeNewswire)
May-28-26 08:00AM	BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure (GlobeNewswire)
08:00AM	Loading…
May-21-26 08:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency (GlobeNewswire)
May-19-26 08:00AM	BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase (GlobeNewswire) +5.64%
May-16-26 01:00AM	BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ... (GuruFocus.com)
May-15-26 08:00AM	BioCardia Reports First Quarter 2026 Business Highlights and Financial Results (GlobeNewswire) -7.34%
May-11-26 05:10PM	BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 (GlobeNewswire)
May-08-26 08:00AM	BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways (GlobeNewswire)
Apr-28-26 08:00AM	BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures (GlobeNewswire)
Apr-20-26 08:00AM	BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure (GlobeNewswire) +5.93%
Apr-02-26 10:11AM	BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP System in Ischemic Heart Failure (GlobeNewswire)
Mar-24-26 11:01PM	BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... (GuruFocus.com)
04:05PM	BioCardia Reports 2025 Business Highlights and Financial Results (GlobeNewswire)
Mar-19-26 07:47PM	BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 (GlobeNewswire)
Mar-17-26 06:00AM	BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA (GlobeNewswire)
Mar-03-26 08:00AM	BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire) -5.92%
Feb-10-26 09:15AM	BioCardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart (GlobeNewswire)
08:00AM	Loading…
Feb-03-26 08:00AM	BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire)
Dec-16-25 08:00AM	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA (GlobeNewswire)
Dec-03-25 08:00AM	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno (GlobeNewswire)
Dec-01-25 08:30AM	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress (GlobeNewswire)
Nov-24-25 08:15AM	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality (GlobeNewswire)
Nov-12-25 04:40PM	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Nov-10-25 08:30AM	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Nov-05-25 07:29PM	BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Oct 16 '26	Buy	0.95	300	285	385,385	Oct 20 05:42 PM
Altman Peter	President and CEO	Oct 15 '26	Buy	0.95	200	190	385,085	Oct 20 05:42 PM
Altman Peter	President and CEO	Sep 29 '26	Buy	1.03	1,000	1,030	384,885	Sep 30 06:51 PM
Altman Peter	President and CEO	Sep 23 '26	Buy	1.05	1,900	1,995	383,885	Sep 23 08:14 PM
Altman Peter	President and CEO	Sep 03 '26	Buy	1.09	800	872	381,985	Sep 04 09:30 PM
Altman Peter	President and CEO	Aug 17 '26	Buy	0.93	5,400	5,022	381,115	Aug 18 12:14 PM
Altman Peter	President and CEO	Aug 13 '26	Buy	0.92	1,900	1,748	375,785	Aug 13 05:43 PM
Altman Peter	President and CEO	Jul 29 '26	Buy	0.78	5,000	3,900	373,885	Jul 29 09:05 PM
Altman Peter	President and CEO	Jul 17 '26	Buy	0.83	500	415	368,885	Jul 20 04:16 PM
Altman Peter	President and CEO	Jul 14 '26	Buy	0.88	2,800	2,464	366,885	Jul 15 04:40 PM
Altman Peter	President and CEO	Jul 15 '26	Buy	0.86	1,500	1,290	368,385	Jul 15 04:40 PM
Altman Peter	President and CEO	Jul 08 '26	Buy	0.97	5,500	5,335	367,485	Jul 10 06:18 PM
Altman Peter	President and CEO	Jul 10 '26	Buy	0.94	1,000	940	369,485	Jul 10 06:18 PM
Altman Peter	President and CEO	Jul 09 '26	Buy	0.90	1,000	900	368,485	Jul 10 06:18 PM
Altman Peter	President and CEO	Jul 08 '26	Buy	0.96	5,400	5,208	361,985	Jul 08 03:30 PM
STERTZER SIMON H	Director	Jun 22 '26	Buy	0.92	70,200	64,584	127,338	Jun 24 06:16 PM
STERTZER SIMON H	Director	Jun 23 '26	Buy	1.00	39,000	39,000	166,338	Jun 24 06:16 PM
Altman Peter	President and CEO	Jun 17 '26	Buy	0.85	1,500	1,275	299,766	Jun 22 06:09 AM
Altman Peter	President and CEO	Jun 18 '26	Buy	0.96	800	768	300,566	Jun 22 06:09 AM
Altman Peter	President and CEO	Jun 09 '26	Buy	0.85	5,000	4,250	298,266	Jun 09 05:37 PM
Altman Peter	President and CEO	May 20 '26	Buy	0.92	1,500	1,380	293,266	May 21 06:14 PM
Altman Peter	President and CEO	May 19 '26	Buy	0.95	200	190	291,766	May 21 06:14 PM
Altman Peter	President and CEO	May 18 '26	Buy	0.92	5,700	5,244	291,566	May 18 08:20 PM
Altman Peter	President and CEO	May 15 '26	Buy	1.02	5,100	5,202	285,866	May 15 05:46 PM
Altman Peter	President and CEO	Apr 29 '26	Buy	1.11	5,000	5,550	280,766	Apr 29 07:40 PM
Altman Peter	President and CEO	Apr 20 '26	Buy	1.23	600	738	275,366	Apr 22 05:04 PM
Altman Peter	President and CEO	Apr 21 '26	Buy	1.23	400	492	275,766	Apr 22 05:04 PM
Altman Peter	President and CEO	Mar 24 '26	Buy	1.24	600	744	274,466	Mar 26 08:05 PM
Altman Peter	President and CEO	Mar 25 '26	Buy	1.22	300	366	274,766	Mar 26 08:05 PM
Altman Peter	President and CEO	Feb 04 '26	Buy	1.13	5,000	5,650	273,866	Feb 04 05:47 PM
Altman Peter	President and CEO	Jan 20 '26	Buy	1.32	600	792	268,566	Jan 21 05:03 PM
Altman Peter	President and CEO	Jan 21 '26	Buy	1.34	300	402	268,866	Jan 21 05:03 PM
Altman Peter	President and CEO	Dec 17 '25	Buy	1.30	900	1,170	267,966	Dec 17 06:32 PM
Altman Peter	President and CEO	Dec 16 '25	Buy	1.37	200	274	267,066	Dec 17 06:32 PM

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

CEODr. Peter A. Altman Ph.D.

Chief Financial OfficerMr. David McClung

Senior Vice President of DevicesMr. Edward M. Gillis

Investor Relations ExecutiveMs. Miranda Peto Benvenuti

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCDA

BioCardia Inc

Upgrade your Finviz experience